Active Volume Stock Update: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO)

10

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) gained 24.15 Percent and closed its previous trading session at $3.29. The stock traded with the average Volume of 3.66 Million at the end of last session.

The company reported its last earnings Actual EPS of $-0.22/share. While, the analyst predicted that the company could provide an EPS of $-0.17/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.05/share which shows an Earnings Surprise of -29.4 Percent.

Sell side analysts plays vital role in buying and selling a stock where 1 analysts rated Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.

The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 28.27% where SMA50 and SMA200 are 86.93% and 169.55% respectively.

The company shows its Return on Assets (ROA) value of -34%. The Return on Equity (ROE) value stands at -123.6%. While it’s Return on Investment (ROI) value is -162.5%.

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) currently has a Weekly Volatility of 13.01% percent while its Monthly Volatility is at 14.18% percent. While talking about Performance of the Stock, Eleven Biotherapeutics, Inc. currently has a Weekly performance of 16.25%, monthly performance percentage is 119.33 percent, Quarterly performance is 265.56 percent, 6 months performance shows a percent value of 383.82% and Yearly Performance is 100.61 percent.

Company Profile:

Eleven Biotherapeutics, Inc. is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal preclinical product candidate consist of  EBI-005, a novel IL-1 receptor antagonist for the topical treatment of dry eye disease and allergic conjunctivitis, EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of certain retinal diseases, such as DME and EBI-028, a novel inhibitor of the cytokine IL-17 for the treatment of uveitis. Eleven Biotherapeutics, Inc. is based in Cambridge, United States.

 

SHARE